Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Hodgkin Disease × tislelizumab × Clear all

Phase

Phase 2 4 Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Small Cell Lung Carcinoma 1 Recurrence 1 Non-Muscle Invasive Bladder Neoplasms 1 Hodgkin Disease 1 Esophageal Squamous Cell Carcinoma 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 2 Brentuximab Vedotin 2 tislelizumab 1 sintilimab 1 prednylidene 1 Watchful Waiting 1 Vinblastine 1 Thiotepa 1 Radiotherapy 1 Prednisolone 1 Pentoxifylline 1 Filgrastim 1 Bendamustine Hydrochloride 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Dalian Medical University

Phase 4 Not yet recruiting

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡